Indian drugmaker Torrent Pharma posts lower quarterly profit on acquisition costs

J B Chemicals and Pharmaceuticals

22/05/2026 13:04

May 22 (Reuters) - Indian drugmaker Torrent Pharmaceuticals TORP.NS reported a 21.9% fall in fourth-quarter profit on Friday, as acquisition-related costs from its deal with J.B. Chemicals and Pharmaceuticals offset strong revenue growth.

Consolidated net profit fell to 3.89 billion rupees ($40.65 million) for the quarter ended March 31, from 4.98 billion rupees a year earlier

The company declared a dividend of 9 rupees per share

Total revenue from operations rose 41.8% year-on-year to 41.97 billion rupees, supported by growth in its domestic formulations business

Total expenses rose nearly 60%, outpacing revenue growth, led by higher employee, finance, and depreciation costs

The drugmaker incurred exceptional costs related to regulatory fees and integration expenses tied to the J.B. Pharma deal

Revenue from India, the company's largest market, grew 43% year-on-year, driven by strong performance in chronic therapies

Revenue from the U.S. rose 31%, while revenue from Brazil increased 30%, supported by recent product launches

Operational EBITDA margin stood at 32.3%, compared with 33% a year ago

($1 = 95.6900 Indian rupees)

 (Reporting by Bipasha Dey in Bengaluru; Editing by Mrigank Dhaniwala)

 ((Bipasha.Dey@thomsonreuters.com;))